News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
2/4/2014 8:19:44 AM
Ongar, UK. 3 February 2014: An initiative is under way to develop new drugs for a devastating tropical disease that threatens almost 70 million people in Africa.
Scientists are beginning a £2.5 million project to design novel treatments for sleeping sickness, which is spread by the bite of the tsetse fly and is prevalent in west and central Africa. It can damage the nervous system and cause coma, organ failure and death.
Existing medicines for the disease can cause debilitating side-effects or can be fatal. Some drugs must be administered using a drip, which makes treatment time-consuming and expensive. Researchers hope to develop safe, effective medicines that can be given easily.
The quest for new treatments will build on previous studies about how the infection occurs. Scientists have shown that the parasite is able to survive in the bloodstream by using enzymes to convert blood sugars into the energy it needs to stay alive. They have identified potential drug compounds that can stop two of these enzymes from functioning, so killing the parasite.
Scientists from the University of Edinburgh, working with the international life sciences contract research organisation Selcia, will design and develop drugs based on these drug compounds. Their aim is to design a drug that will be effective in small doses, and will work even on advanced infections. The 30-month project, funded by the Wellcome Trust, will seek to test the compounds in the lab and in mice, ahead of further studies that could involve human trials.
New treatments could be developed into veterinary medicines for infections caused by the same parasite in livestock, which cost farmers about US$2 billion a year.
Professor Malcolm Walkinshaw, of the University of Edinburgh’s School of Biological Sciences, said: “Sleeping sickness is a widespread, neglected disease which, if left untreated, is invariably fatal and drugs are poorly effective. We hope to develop new forms of treatment that can be easily administered and will eventually help curb the disease’s impact.”
Dr Hans Fliri, Chairman and CEO of Selcia, said: “We are delighted to collaborate with the University of Edinburgh’s School of Biological Sciences. Selcia has made no secret of its determination to develop strong links with academic research teams. We see these partnerships as a key strategic element of our growing integrated drug discovery offer.”
For further information, please contact:
Professor Malcolm Walkinshaw, School of Biological Sciences, tel 0131 650 7056; Malcolm.Walkinshaw@ed.ac.uk
Catriona Kelly, Press and PR Office, tel 0131 651 4401; Catriona.Kelly@ed.ac.uk
Andy Matthews, O2PR Ltd, tel +44 (0)7967 153754; firstname.lastname@example.org
Dave Roberts, Selcia Ltd, tel +44 (0) 1277 367000, email@example.com
Selcia Limited is a privately held contract research organisation with two operating divisions, Selcia Discovery which provides integrated small molecule drug discovery services to the global life science industry; these services include in vitro biology, screening, fragment screening, medicinal, organic and analytical chemistry, and in vitro ADME/PK evaluation as well as in vivo PK (with a strategic partner) and Selcia Radiolabelling which specialises in 14C GMP radiolabelling.
Press release issued on behalf of Selcia by Andy Matthews
Tel: +44 (0)1223 309500
Mob: +44 (0)7967 153753
Help employers find you! Check out all the jobs and post your resume.